Medscape |
GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers
FierceBiotech GSK's injection, mepolizumab, works by blocking the protein interleukin-5 to prevent buildups of white blood cells in the lungs that can exacerbate asthma. The company is angling to get the drug approved as a treatment for sufferers of severe asthma … FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma GlaxoSmithKline plc (ADR) Wins FDA Panel Backing For Severe Asthma Drug Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers |
View full post on asthma – Google News
